Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 11/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249963 | 0.84 | CHRM3 (0.45) | CHRM3CNR2CNR1TRPV4 | |
| SCHEMBL19365803 | 0.82 | MAPK13 (0.46) | IDH2 | |
| Trifluoroacetic Acid SCHEMBL16238254 | 0.82 | FAAH (0.43) | CHRM3CNR2TRPV4 | |
| SCHEMBL19364920 | 0.82 | IDH2 (0.40) | IDH2APP | |
| SCHEMBL19865068 | 0.81 | CHRM3 (0.46) | CHRM3CNR2CNR1TRPV4HTR6 | |
| SCHEMBL19706975 | 0.80 | IDH2 (0.36) | IDH2 | |
| SCHEMBL19706685 | 0.80 | IDH2 (0.41) | CNR2CNR1IDH2 | |
| SCHEMBL19706053 | 0.79 | IDH2 (0.39) | CNR2IDH2 | |
| SCHEMBL19706045 | 0.78 | IDH2 (0.35) | CNR2IDH2 | |
| SCHEMBL19706914 | 0.78 | IDH2 (0.38) | CNR2CNR1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CHRM3 4183/4885CNR2 2514/4885CNR1 2946/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CHRM3 4183/4885CNR2 2514/4885CNR1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.